This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Symptom Evaluation After Cessation of a Proton Pump Inhibitor in Healthy Volunteers

This study has been completed.
Information provided by:
Sahlgrenska University Hospital, Sweden Identifier:
First received: June 4, 2009
Last updated: NA
Last verified: June 2009
History: No changes posted
The purpose of this study is to determine whether proton pump inhibitor (PPI) induced hypersecretion leads to acid related symptoms after treatment in healthy volunteers.

Condition Intervention
Healthy Drug: Pantoprazole Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Basic Science
Official Title: Symptom Evaluation After Cessation of a Proton Pump Inhibitor in Healthy Volunteers

Resource links provided by NLM:

Further study details as provided by Sahlgrenska University Hospital, Sweden:

Primary Outcome Measures:
  • To evaluate whether healthy volunteers, treated with PPI for four weeks, develop acid-related symptoms after cessation of PPI therapy.

Secondary Outcome Measures:
  • To evaluate whether there is a correlation between markers for acid secretion such as gastrin and chromogranin-A and the development of dyspeptic symptoms.

Enrollment: 50
Study Start Date: January 2006
Study Completion Date: October 2006
Primary Completion Date: October 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Pantoprazole Drug: Pantoprazole
40 mg pantoprazole once daily for 28 days
Placebo Comparator: Placebo Drug: Placebo
identical placebo once daily for 28 days

Detailed Description:
Treatment with proton pump inhibitors (PPI) has been shown to cause rebound hypersecretion of gastric acid. The clinical significance of this phenomenon is however unclear. This study aims to examine whether or not healthy volunteers, who over a relatively short period of time treated with a PPI, develop dyspeptic symptoms after cessation of therapy. Dyspeptic symptoms will be measured subjectively using a validated questionnaire, which is filled out each day. Gastric acid will be measured indirectly with measurement of acid secretion markers (Gastrin and chromogranin-A).

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy volunteers
  • 18-70 years of age
  • Informed consent
  • No prior history of any GI disorder

Exclusion Criteria:

  • Dyspeptic complaints
  • H. pylori infection
  • Ongoing treatment with pain-relieving medications (i.e., NSAID)
  • Pregnancy or breast feeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00915239

Sahlgrenska Univeristy Hospital
Gothenburg, Sweden, 413 45
Sponsors and Collaborators
Sahlgrenska University Hospital, Sweden
  More Information

Responsible Party: Einar Björnsson, Sahlgrenska University Hospital Identifier: NCT00915239     History of Changes
Other Study ID Numbers: SUS/KUS2
Study First Received: June 4, 2009
Last Updated: June 4, 2009

Keywords provided by Sahlgrenska University Hospital, Sweden:

Additional relevant MeSH terms:
Proton Pump Inhibitors
Anti-Ulcer Agents
Gastrointestinal Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017